Inflation

Mullen Subsidiary, Bollinger Motors, Names Next 2 Dealers in 7 States and 11 Locations

Retrieved on: 
Tuesday, March 5, 2024
Bollinger Motors, Inflation, Equipment, IBN, B4, Safety, Bollinger

The Bollinger B4 Chassis Cab is an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input.

Key Points: 
  • The Bollinger B4 Chassis Cab is an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input.
  • Bollinger’s unique chassis design protects the 158-kilowatt-hour battery pack and components to offer unparalleled capability and safety in the commercial market.
  • The company anticipates deliveries of the Bollinger B4 to begin in the second half of 2024.
  • “We are building our national dealer network very strategically to ensure that they share Bollinger’s commitment to quality and customer service,” said Robert Bollinger, founder and CEO of Bollinger Motors.

Broadwind Announces Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Tuesday, March 5, 2024
Yoy, Inflation, Total, Mining, Investment, Growth, Appendix, GAAP, Steel, Economics, IRA, Hand, Environment, Wind

The Company reported net income of $1.1 million, or $0.05 per diluted share in the fourth quarter 2023, compared to a net loss ($2.9) million, or ($0.14) per basic share, in the fourth quarter 2022.

Key Points: 
  • The Company reported net income of $1.1 million, or $0.05 per diluted share in the fourth quarter 2023, compared to a net loss ($2.9) million, or ($0.14) per basic share, in the fourth quarter 2022.
  • The Company reported adjusted EBITDA, a non-GAAP measure, of $4.4 million in the fourth quarter 2023, compared to $0.2 million in the prior-year period.
  • Fourth quarter results reflect the positive impact of increased tower utilization and benefits derived from advanced manufacturing production credits associated with the Inflation Reduction Act (“IRA”).
  • The segment reported non-GAAP adjusted EBITDA of $1.3 million in the fourth quarter 2023, versus $0.8 million in the fourth quarter 2022.

Atlantica Reports 2023 Financial Results

Retrieved on: 
Friday, March 1, 2024
Inflation, Atlantica, Kilowatt-hour, Investment, Natural gas, Growth, Plant, PPA, Risk, Line of credit, Policy, COD, Professional, Insurance, Wind, Renewable energy

On the other hand, production in our wind assets in the U.S. decreased due to lower wind resource during 2023.

Key Points: 
  • On the other hand, production in our wind assets in the U.S. decreased due to lower wind resource during 2023.
  • Production also decreased in Kaxu mostly due to the unscheduled outage that started in September 2023.
  • As of December 31, 2023, cash at Atlantica’s corporate level was $33.0 million, compared with $60.8 million as of December 31, 2022.
  • Atlantica currently has a pipeline of projects under development of approximately 2.2 GW12 of renewable energy and 6.0 GWh12 of storage.

New Research on Federal Infrastructure, Manufacturing, Climate Investments Shows Immense Job Opportunities and Workforce Needs

Retrieved on: 
Wednesday, February 28, 2024
CHIPS, Inflation, Woman, Investment, Transport, PERI, University, Distinguishing, Employment, Science, Economics, Occupation, Workforce, Travel, Nursing

It found:

Key Points: 
  • It found:
    Roughly two-thirds of direct job creation is expected to take place in the construction and manufacturing sectors, representing 453,000 jobs and 230,000 jobs respectively.
  • The job sectors that will see growth contrast sharply with how our economy has been trending.
  • Forty-eight specific occupations that are likely to experience significant increases in demand through the direct jobs channel resulting from investments.
  • We need a holistic approach to make sure we have the workforce that meets the moment.”
    Read a data brief with these findings here: https://nationalskillscoalition.org/resource/publications/data-infrastru...

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

Retrieved on: 
Monday, February 26, 2024
Human services, Inflation, AAAAI, Research, Investment, Growth, GAAP, HAE, Tranche, Webcast, Patient, Public expenditure, BioCryst Pharmaceuticals, Net, EPS, Workforce, American Academy, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The number of new ORLADEYO prescribers in the fourth quarter of 2023 (Q4 2023) was the largest number of new prescribers of any quarter in 2023.
  • The increase was primarily due to $90.9 million in ORLADEYO net revenue in the fourth quarter of 2023, compared to $70.7 million in the fourth quarter of 2022.
  • Revenue in the fourth quarter of 2023 also included $2.3 million of net revenue from RAPIVAB related sales, compared to $8.7 million in the fourth quarter of 2022.
  • Interest expense was $24.6 million in the fourth quarter of 2023, compared to $26.5 million in the fourth quarter of 2022.

Century Aluminum Company Reports Fourth Quarter 2023 Results

Retrieved on: 
Wednesday, February 21, 2024
Century, Acquisition, Inflation, Adjustment, Safety, GAAP, Pharmaceutical industry

In the fourth quarter of 2023, shipments of primary aluminum increased 1% sequentially.

Key Points: 
  • In the fourth quarter of 2023, shipments of primary aluminum increased 1% sequentially.
  • Net sales for the fourth quarter of 2023 decreased by 6% sequentially due to lower realized aluminum prices.
  • Thus, Century reported an adjusted net income of $40.0 million for the fourth quarter of 2023, a $53.8 million improvement sequentially.
  • Adjusted EBITDA attributable to Century stockholders for the fourth quarter of 2023 was $57.1 million.

Aemetis Announces Updated Five Year Plan Projecting Growth to $1.95 Billion of Revenue and $645 Million of Adjusted EBITDA in 2028

Retrieved on: 
Tuesday, February 20, 2024
Carbon, Engineering, Inflation, AI, Ethanol, Aviation, LCFS, Natural gas, Growth, Sale, CEQA, Oil, CCUS, CO2, Mechanical vapor recompression, Electricity, EPA, IRA, MVR, USDA, RNG, Renewable energy

The 2024 Plan states revenues are expected to grow at a compound annual growth rate of 38%, and adjusted EBITDA is expected to grow at a projected compound annual growth rate of 83% for the years 2024 to 2028.

Key Points: 
  • The 2024 Plan states revenues are expected to grow at a compound annual growth rate of 38%, and adjusted EBITDA is expected to grow at a projected compound annual growth rate of 83% for the years 2024 to 2028.
  • The presentation also describes the tax credits expected to be received by Aemetis from the Inflation Reduction Act (IRA) for its renewable fuel and sequestration projects.
  • “Additionally, Aemetis closed $50 million of new USDA funding and received $55 million from the sale of IRA tax credits in the past year.
  • The Five Year Plan for Aemetis Dairy RNG operations projects revenues will grow from $18 million in 2024 to $190 million in 2028, while Dairy RNG project EBITDA is expected to expand from $7 million in 2024 to $123 million in 2028.

45L Energy Efficient Tax Credit (2024): Guide on Requirements and How To Claim Published by Better Business Advice

Retrieved on: 
Friday, March 8, 2024
Professional Services, Other Energy, Residential Building & Real Estate, Energy, Construction & Property, Building Systems, Accounting, Acquisition, Inflation, ETS, IECC, Partnership, International Energy Conservation Code, Heat, IRS, Certification, EPA, IRA, Act, Credit, Renewable energy

Better Business Advice has released a comprehensive guide on how to claim the 45L Energy Efficient Tax Credit, highlighting Engineered Tax Services (ETS) as the go-to tax expert for navigating this federal incentive.

Key Points: 
  • Better Business Advice has released a comprehensive guide on how to claim the 45L Energy Efficient Tax Credit, highlighting Engineered Tax Services (ETS) as the go-to tax expert for navigating this federal incentive.
  • The 45L Energy Efficient Tax Credit, a federal incentive, encourages the building of energy-efficient residences by offering credits from $500 to $5,000 per unit, based on the property's certification.
  • A significant enhancement comes with the merger of the 45L Tax Credit with Low-Income Housing Tax Credits (LIHTCs), bolstering the effectiveness of the credit.
  • Better Business Advice's guide to claiming the 45L Energy Efficient Tax Credit, with Engineered Tax Services recommended as the tax expert, is set to empower stakeholders in the residential construction industry to embrace sustainable practices while leveraging federal incentives for energy efficiency.

GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise

Retrieved on: 
Thursday, March 7, 2024
Infectious Diseases, General Health, Health, Other Health, Inflation, Senior, Immunization, GSK, Education, Physician, Hope, Entrepreneurship, Vaccine, Vaccination, American Lung Association, Patient, Request, IRA, Health equity, Infection, Medicaid, GSK plc, Pharmaceutical industry

GSK plc (LSE/NYSE: GSK) today announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced additional funding and new data and resources under the COiMMUNITY Initiative to help achieve higher adult vaccination rates and health equity in the US and address ongoing barriers to adult immunization.
  • The COiMMUNITY Initiative complements recent industry and regulatory efforts to expand and improve adult vaccine availability, coverage and access.
  • GSK is equipping healthcare providers and their patients with simple tools to spur action and follow through on vaccination.
  • GSK will also continue to share new resources, tools and best practices in adult vaccine confidence and delivery via interactive webinars.

Monoamine Oxidase Type-B (MAO-B) Inhibitors for 7 MM: Market Size, Target Population, Competitive Landscape & Forecasts, 2034 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Health, Pharmaceutical, Therapy, Key, Inflation, Competitive landscape, Monoamine oxidase, Physician, News, Opinion, SWOT, EU4, Inhibitor, Safety, HTA, Patient, Disease, Drug, Mutation, Pharmaceutical industry

The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Monoamine Oxidase Type-B (MAO-B) Inhibitors market report provides insights around existing treatment practices in patients with Monoamine Oxidase Type-B (MAO-B) Inhibitors, approved (if any) and emerging Monoamine Oxidase Type-B (MAO-B) Inhibitors, market share of individual therapies, patient pool eligible for treatment with Monoamine Oxidase Type-B (MAO-B) Inhibitors, along with current and forecasted 7MM Monoamine Oxidase Type-B (MAO-B) Inhibitors market size from 2020-2034 by therapies and by indication.
  • This section will include details on changing Monoamine Oxidase Type-B (MAO-B) Inhibitors market dynamics post initiation of clinical development activities of the inhibitor.
  • The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Monoamine Oxidase Type-B (MAO-B) Inhibitors.